A PHASE 2B/3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
Brief description of study
The purpose of this study is to learn more about the effects and safety of the study drug (PF-06651600) for treating alopecia areata. The study drug is an investigational drug because it is not approved by the US Food and Drug Administration (FDA). Alopecia areata is an autoimmune disease, where the immune system attacks your own body. With alopecia areata, it’s the hair follicles that are attacked. This causes the hair to come out. The amount of hair loss is different in everyone. Some people lose it only in a few spots. Others can lose all the hair on their head (alopecia areata totalis) or the entire body (alopecia areata universalis).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.